I fear that this policy could lead to a sort of public shaming of companies that are trying to benefit patients.
Michael Burgess: “I fear that this policy could lead to a sort of public shaming of companies that are trying to benefit patients.”
Editor's note · Context
Burgess expresses concern about potential negative impacts of a policy on drug manufacturers.
Share
More from Michael Burgess
I urge adoption of the amendment. It is important, with $31 trillion in national debt, that we be good stewards of taxpayer dollars. The gentleman is right. I have pursued this for a number of years, but it is because it is a noble cause…
This is a national emergency. This is something we have got to address and save Americans, 200 every day.
I will simply underscore the fact that entry- level chemists at the EPA are hired at much higher than the GSA rate. These are not highly sought-after scientists. These are entry-level applicants, and there is no shortage of applicants for…
I led a letter to the FDA asking them to reclassify naloxone to where you could get it without a prescription.





